1. Preface

• 1.1 Report Description and Scope

• 1.2 Research Objectives

• 1.3 Target Audience

• 1.4 Research Methodology Overview

2. Executive Summary

• 2.1 Market Snapshot

• 2.2 Key Market Findings

• 2.3 Analyst Recommendations

3. Market Overview

• 3.1 Introduction to the Global Opioids Market

• 3.2 Market Definition and Classification

• 3.3 Macro-Economic Factors Influencing the Market

• 3.4 Regulatory Framework and Compliance Standards

• 3.5 Opioid Crisis Overview and Evolving Policy Landscape

4. Market Dynamics

• 4.1 Market Drivers

  • 4.1.1 Rising Prevalence of Chronic Pain Conditions

  • 4.1.2 Growing Geriatric Population and Age-Related Disorders

  • 4.1.3 Increasing Number of Surgical Procedures Globally

  • 4.1.4 Approval and Launch of New Opioid Formulations

  • 4.1.5 Rising Demand for Palliative and Cancer Pain Management

• 4.2 Market Restraints

  • 4.2.1 High Risk of Addiction, Abuse, and Dependency

  • 4.2.2 Stringent Regulatory Oversight and Prescribing Limitations

  • 4.2.3 Negative Public Perception and Social Stigma

  • 4.2.4 Legal Liabilities and Litigation Against Manufacturers

• 4.3 Market Opportunities

  • 4.3.1 R&D in Abuse-Deterrent Opioid Formulations

  • 4.3.2 Expanding Market in Asia Pacific and Emerging Economies

  • 4.3.3 Growing Demand for Retail Pharmacy Distribution Channels

  • 4.3.4 Hybrid Opioid-Neurokinin Receptor Research Advancements

• 4.4 Market Challenges

  • 4.4.1 Cannabis and Non-Opioid Alternatives as Market Disruptors

  • 4.4.2 Supply Chain and Raw Material Dependency Issues

  • 4.4.3 Counterfeit and Illicit Opioid Drug Proliferation

5. Market Trends Analysis

• 5.1 Shift Toward Extended-Release and Long-Acting Opioid Formulations

• 5.2 Innovation in Opioid Manufacturing and Formulation Techniques

• 5.3 Increasing Generic Drug Launches in the Opioid Segment

• 5.4 Adoption of Digital Health Platforms in Opioid Management

• 5.5 Strategic Mergers, Acquisitions, and Licensing Activities

6. Global Opioids Market — Segmentation Analysis

6.1 By Product Type

• 6.1.1 IR/Short-Acting Opioids

  • Codeine

  • Oxycodone

  • Hydrocodone

  • Fentanyl

  • Morphine

  • Hydromorphone

  • Oxymorphone

  • Others

• 6.1.2 ER/Long-Acting Opioids

  • Codeine (ER)

  • Oxycodone (ER)

  • Hydrocodone (ER)

  • Fentanyl (ER)

  • Morphine (ER)

  • Methadone

  • Others

6.2 By Application

• 6.2.1 Pain Management

  • Postoperative Pain

  • Cancer Pain

  • Chronic Non-Cancer Pain

• 6.2.2 Anesthesia

• 6.2.3 Cough Treatment

• 6.2.4 Diarrhea Treatment

• 6.2.5 De-addiction / Opioid Use Disorder (OUD)

6.3 By Route of Administration

• 6.3.1 Oral

• 6.3.2 Injectable

• 6.3.3 Transdermal

• 6.3.4 Others (Sublingual, Intranasal, etc.)

6.4 By Distribution Channel

• 6.4.1 Hospital Pharmacies

• 6.4.2 Retail Pharmacies

• 6.4.3 Online Pharmacies

• 6.4.4 Others

7. Regional Market Analysis

7.1 North America

• 7.1.1 U.S. Opioids Market Overview

• 7.1.2 Canada Opioids Market Overview

• 7.1.3 Regulatory Environment in North America

• 7.1.4 Market Size, Share, and Forecast (2026–2033)

7.2 Europe

• 7.2.1 Germany

• 7.2.2 United Kingdom

• 7.2.3 France

• 7.2.4 Italy

• 7.2.5 Spain

• 7.2.6 Rest of Europe

• 7.2.7 Market Size, Share, and Forecast (2026–2033)

7.3 Asia Pacific

• 7.3.1 China

• 7.3.2 Japan

• 7.3.3 India

• 7.3.4 Australia

• 7.3.5 South Korea

• 7.3.6 Rest of Asia Pacific

• 7.3.7 Market Size, Share, and Forecast (2026–2033)

7.4 Latin America

• 7.4.1 Brazil

• 7.4.2 Mexico

• 7.4.3 Argentina

• 7.4.4 Rest of Latin America

• 7.4.5 Market Size, Share, and Forecast (2026–2033)

7.5 Middle East & Africa

• 7.5.1 Saudi Arabia

• 7.5.2 UAE

• 7.5.3 South Africa

• 7.5.4 Rest of Middle East & Africa

• 7.5.5 Market Size, Share, and Forecast (2026–2033)

8. Competitive Landscape

• 8.1 Market Concentration and Competitive Intensity

• 8.2 Key Strategic Developments (2023–2026)

  • Mergers and Acquisitions

  • Product Launches and Approvals

  • Partnerships, Collaborations, and Licensing Agreements

  • Expansions and Geographic Footprint

• 8.3 Competitive Benchmarking Matrix

• 8.4 Market Share Analysis of Key Players

9. Company Profiles

The final report includes a complete list of companies

9.1 Purdue Pharma L.P.

• Company Overview

• Financial Performance

• Product Portfolio

• Strategic Initiatives

• SWOT Analysis

9.2 Johnson & Johnson (Janssen Pharmaceuticals, Inc.)

9.3 Pfizer, Inc.

9.4 Teva Pharmaceutical Industries Ltd.

9.5 AbbVie Inc.

9.6 Hikma Pharmaceuticals PLC

9.7 Sanofi

9.8 Sun Pharmaceutical Industries Ltd.

9.9 Endo International plc

9.10 Mallinckrodt Pharmaceuticals

9.11 Fresenius Kabi

9.12 Amneal Pharmaceuticals LLC

9.13 Grünenthal GmbH

9.14 Lupin Limited

9.15 Trevena, Inc.

10. Supply Chain & Value Chain Analysis

• 10.1 Raw Material Sourcing and API Suppliers

• 10.2 Manufacturing and Formulation Process

• 10.3 Distribution Network and Logistics

• 10.4 End-User Analysis

11. Pricing Analysis

• 11.1 Average Selling Price Trends by Product Type

• 11.2 Regional Pricing Dynamics

• 11.3 Impact of Generic Entry on Pricing

12. Regulatory and Legal Landscape

• 12.1 U.S. FDA Regulations and Scheduling of Opioids

• 12.2 DEA Compliance and Controlled Substance Act

• 12.3 International Narcotic Control Board (INCB) Guidelines

• 12.4 Recent Legal Settlements and Their Market Impact

13. Investment and Funding Landscape

• 13.1 R&D Expenditure Trends in the Opioids Sector

• 13.2 Venture Capital and Private Equity Activity

• 13.3 Government Funding and Grant Programs

14. Future Outlook and Strategic Recommendations

• 14.1 Market Growth Projections (2026–2033)

• 14.2 White Space and Unmet Needs

• 14.3 Recommendations for Market Participants

15. Disclaimer